126
- Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clini-
cal remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology.
2012;142(2):257–65; e251-253. - Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab
pegol for Crohn’s disease. N Engl J Med. 2007;357(3):239–50. - Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab’)2,
but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut.
2011;60(1):41–8. - Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy
for ulcerative colitis. N Engl J Med. 2013;369(8):699–710. - Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy
of infliximab in Crohn’s disease. N Engl J Med. 2003;348(7):601–8. - Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydro-
cortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized
controlled trial. Gastroenterology. 2003;124(4):917–24. - Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum inflix-
imab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin
Gastroenterol Hepatol. 2006;4(10):1248–54. - Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum
infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative
colitis. Gut. 2010;59(1):49–54. - Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunoge-
nicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology.
2009;137(5):1628–40. - Sandborn WJ, Abreu MT, D’Haens G, et al. Certolizumab pegol in patients with moderate
to severe Crohn’s disease and secondary failure to infliximab. Clin Gastroenterol Hepatol.
2010;8(8):688–695.e682. - Imaeda H, Takahashi K, Fujimoto T, et al. Clinical utility of newly developed immunoas-
says for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with
Crohn’s disease. J Gastroenterol. 2014;49(1):100–9. - Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflamma-
tory bowel disease and factors implicated in treatment response. Ther Adv Gastroenterol.
2013;6(4):269–93. - Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic
monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507. - Scott FI, Lichtenstein GR. Therapeutic drug monitoring of anti-TNF therapy in inflammatory
bowel disease. Curr Treat Options Gastroenterol. 2014;12(1):59–75. - Van Assche G, Magdelaine-Beuzelin C, D’Haens G, et al. Withdrawal of immunosuppres-
sion in Crohn’s disease treated with scheduled infliximab maintenance: a randomized trial.
Gastroenterology. 2008;134(7):1861–8. - Reinisch W, Feagan BG, Rutgeerts PJ, et al. Infliximab concentration and clinical outcome in
patients with ulcerative colitis. Gastroenterology. 2012;142(5):S114; [Abstract]. - Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and
decrease of C-reactive protein level are associated with durable sustained response to inflix-
imab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63(11):1721–7. - Reinisch W, Colombel JF, Sandborn WJ, et al. Factors associated with short- and long-term
outcomes of therapy for Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(3):539–547.
e532. - Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-alpha therapy: serum levels of inflix-
imab and adalimumab associate with mucosal healing in patients with inflammatory bowel
diseases. Clin Gastroenterol Hepatol. 2016;14(4):550–57.
F.I. Scott and M.T. Osterman